🇺🇸 FDA
Pipeline program

TPO-RAs

IIT2022047

Approved small_molecule active

Quick answer

TPO-RAs for Primary Immune Thrombocytopenia (ITP) is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Primary Immune Thrombocytopenia (ITP)
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials